In FY2022 ended March, Accrelist’s revenue for its medical aesthetics services segment increased by 71.4% to $10.8 million due to the expansion of existing clinics and the opening of new clinics, as well as enhanced marketing.
The company aims to broaden its revenue stream through its skincare products business A.M Skincare — its wholly owned subsidiary which complements its expanding clinic network.
Accrelist remains confident in the long-term prospects of its medical aesthetics business and will explore potential opportunities for long-term growth both in Singapore and overseas.
Shares in Accrelist closed 0.2 cents lower or -5% down on Oct 25 at 3.8 cents.
